The Journey Ahead: Suppressive Therapy and Prognosis
At a Glance
After initial IV treatment for neonatal HSV, babies typically undergo 6 months of suppressive therapy with oral acyclovir. This daily medication helps protect brain development and reduces viral recurrences. Long-term prognosis depends on the initial disease classification, requiring close follow-up.
Completing the initial 14-to-21-day course of intravenous (IV) acyclovir is a major milestone for your baby. However, for most infants, the journey continues with suppressive therapy and careful long-term monitoring. This phase is designed to protect your baby’s developing brain and prevent the virus from returning.
The 6-Month Protection Plan: Suppressive Therapy
After finishing the IV medication in the hospital, standard care includes starting an oral version of the same medicine (liquid acyclovir) [1][2].
- The Goal: Taking this medicine daily for 6 months helps the brain continue to develop without interference from the virus. It also significantly reduces the frequency of skin recurrences (new blisters) [3][4].
- Neurodevelopmental Impact: Research shows that babies with Central Nervous System (CNS) disease who take suppressive acyclovir for 6 months have better neurodevelopmental outcomes than those who do not [4][5].
- Monitoring: While on this medicine, your baby will need regular blood tests (often monthly) to check their absolute neutrophil count (ANC), as the medicine can sometimes lower the white blood cells that fight infection [6][7].
Understanding the Long-Term Outlook
Every baby’s journey is different, but doctors use the initial classification of the disease to help guide expectations for the future.
Skin, Eye, and Mouth (SEM) Disease
- Prognosis: The outlook for babies with SEM disease is generally excellent [8].
- Outcome: Approximately 88% of these children reach age two with typical neurodevelopmental milestones [9].
- Recurrence: These babies are the most likely to have “breakthrough” skin blisters during or after therapy, but these are usually easily managed [3].
Disseminated (Whole-Body) Disease
- Prognosis: Disseminated disease is the most severe and life-threatening form of neonatal HSV. Even with aggressive treatment, it carries a high mortality rate (around 30%) because of the overwhelming stress on the infant’s internal organs [9][10]. It is incredibly difficult to hear, but your care team will monitor your baby’s organ function closely during this critical window.
- Outcome: If a baby survives the acute infection phase, their developmental outlook is encouraging. About 75% of survivors reach age two without obvious neurological impairment [11].
Central Nervous System (CNS) Disease
- Prognosis: This classification requires the most intensive long-term follow-up because the brain was directly involved [11][12].
- Outcome: About 55% of survivors show typical development at age two, while others may experience challenges such as motor delays or seizures [11][13].
Navigating Skin Recurrences
It is common for the virus to occasionally “wake up” and cause a few blisters on the skin, even while a baby is on suppressive therapy [3][1].
- What it looks like: Small, clear blisters that may look like a scratch or a “pimple.”
- What to do: Do not wait. Seek immediate medical attention (such as taking the baby to the ER or calling your on-call pediatrician) while simultaneously notifying your Infectious Disease team. They may need to quickly adjust the dose or temporarily switch back to IV medication [5].
- Safety Precautions: Never pop or squeeze a blister. Keep it covered if possible, and practice strict hand hygiene to avoid accidentally spreading the virus to the baby’s eyes or brain (autoinoculation) or contracting it yourself.
Your Support Team
Because the first few years are a time of rapid brain growth, your baby will likely have a “team” of specialists. This often includes:
- Pediatric Infectious Disease Specialist: To manage the acyclovir and monitor blood work.
- Pediatric Neurologist: To monitor brain development and watch for any signs of seizures or tone issues [14][13].
- Developmental Pediatrician: To track milestones like rolling, crawling, and speaking.
- Audiologist: To perform hearing screens, as viral infections can sometimes affect the auditory nerves.
- Ophthalmologist: To ensure no long-term inflammation is affecting the eyes.
By staying consistent with the suppressive medicine and attending all follow-up appointments, you are giving your baby the strongest possible foundation for the years ahead.
Common questions in this guide
Why does my baby need 6 months of suppressive therapy for neonatal HSV?
Why does my baby need monthly blood tests while taking acyclovir?
What should I do if my baby gets a new skin blister while on suppressive therapy?
What is the long-term outlook for a baby with Skin, Eye, and Mouth (SEM) HSV?
What specialists will my baby need to see after neonatal HSV treatment?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is the specific plan for monitoring my baby's white blood cell count (ANC) while they are on the 6-month suppressive therapy?
- 2.How often will we need to visit the Pediatric Infectious Disease specialist for follow-up?
- 3.What specific developmental milestones should I be watching for over the next few months?
- 4.What should I do if I notice a new skin blister while my baby is on the suppressive medicine?
- 5.When should we schedule the first evaluation with a developmental pediatrician, neurologist, or audiologist?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Delayed Recurrence of Herpes Simplex Virus Infection in the Central Nervous System After Neonatal Infection and Completion of Six Months of Suppressive Therapy.
Henderson B, Kimberlin DW, Forgie SE
Journal of the Pediatric Infectious Diseases Society 2017; (6(4)):e177-e179 doi:10.1093/jpids/pix017.
PMID: 28379476 - 2
[Neonatal herpes: Epidemiology, clinical manifestations and management. Guidelines for clinical practice from the French College of Gynecologists and Obstetricians (CNGOF)].
Renesme L
Gynecologie, obstetrique, fertilite & senologie 2017; (45(12)):691-704 doi:10.1016/j.gofs.2017.10.005.
PMID: 29132771 - 3
Real-World Data on Cutaneous Recurrences Following Neonatal Herpes Simplex Virus Disease.
Kimberlin DW
Journal of the Pediatric Infectious Diseases Society 2022; (11(11)):504-505 doi:10.1093/jpids/piac110.
PMID: 36264543 - 4
[How I treat… a neonatal Herpes simplex virus infection].
Godet ML, Pêtre J, Bernier V, et al.
Revue medicale de Liege 2017; (72(5)):223-226.
PMID: 28520319 - 5
Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report.
Kato K, Hara S, Kawada J, Ito Y
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2015; (21(12)):879-81.
PMID: 26390826 - 6
Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections.
Ericson JE, Gostelow M, Autmizguine J, et al.
The Pediatric infectious disease journal 2017; (36(4)):369-373 doi:10.1097/INF.0000000000001451.
PMID: 27977557 - 7
Factors associated with acyclovir nephrotoxicity in children: data from 472 pediatric patients from the last 10 years.
Yalçınkaya R, Öz FN, Kaman A, et al.
European journal of pediatrics 2021; (180(8)):2521-2527 doi:10.1007/s00431-021-04093-0.
PMID: 33956193 - 8
[The Spanish Society of Paediatric Infectious Diseases guidelines on the prevention, diagnosis and treatment of neonatal herpes simplex infections].
Anales de pediatria 2018; (89(1)):64.e1-64.e10 doi:10.1016/j.anpedi.2018.01.004.
PMID: 29453157 - 9
Herpes simplex virus disease in infants younger than 90 days: a British Paediatric Surveillance Unit study.
Dudley JRR, Shears A, Yan G, et al.
Archives of disease in childhood 2026; (111(5)):423-429 doi:10.1136/archdischild-2025-329176.
PMID: 40897403 - 10
Proteomic profiling of neonatal herpes simplex virus infection on dried blood spots.
Dungu KHS, Hagen CM, Bækvad-Hansen M, et al.
Communications medicine 2024; (4(1)):268 doi:10.1038/s43856-024-00711-8.
PMID: 39695338 - 11
Neonatal Herpes Simplex Virus Infection: Epidemiology and Outcomes in the Modern Era.
Melvin AJ, Mohan KM, Vora SB, et al.
Journal of the Pediatric Infectious Diseases Society 2022; (11(3)):94-101 doi:10.1093/jpids/piab105.
PMID: 34894240 - 12
Characteristics of neonatal herpes simplex central nervous system disease in Australia (1997-2020).
Teutsch S, Berkhout A, Raynes-Greenow C, et al.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2023; (165()):105526 doi:10.1016/j.jcv.2023.105526.
PMID: 37379780 - 13
The Many Faces of Neurological Neonatal Herpes Simplex Virus Infection.
Shahoud F, Rathore MH, Shah CC, Alissa R
Cureus 2023; (15(7)):e41580 doi:10.7759/cureus.41580.
PMID: 37559852 - 14
Characteristics of neonatal herpes simplex virus infections in Germany: results of a 2-year prospective nationwide surveillance study.
Kidszun A, Bruns A, Schreiner D, et al.
Archives of disease in childhood. Fetal and neonatal edition 2022; (107(2)):188-192 doi:10.1136/archdischild-2021-321940.
PMID: 34257101
This page explains suppressive therapy and prognosis for neonatal HSV for educational purposes only. Always consult your pediatric infectious disease team for your baby's specific medical management and long-term follow-up care.
Get notified when new evidence is published on Congenital herpes simplex virus infection.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.